Treatment

A new study tested patient-derived organoids (PDOs) from ascites fluid to improve treatment for advanced ovarian cancer. These 3D organoids, created with an 86% success rate, closely replicated the genetics and structure of patients’ tumors, allowing researchers to predict responses to chemotherapy and targeted drugs. Lab results with cisplatin and PARP inhibitors matched patients’ actual one-year […]

Pancreatic cancer progress is being driven by three main areas: prevention, new treatment technology, and artificial intelligence. Because there is no standard screening for the general public, prevention focuses on quitting smoking, maintaining a healthy weight, and monitoring family history. Doctors also encourage genetic testing for high-risk individuals and are studying the link between high

Results from the Phase 1 DAREON-7 trial, presented at the North American Neuroendocrine Tumor Society (NANETS) 2025 Symposium, showed that adding obrixtamig, a T-cell engager, to standard chemotherapy produced strong responses in patients with DLL3-positive neuroendocrine carcinomas. The study reported a 72% objective response rate, with 88% of patients achieving disease control. The median duration

New study shows that Orca-T, a high-precision donor cell therapy, can be reliably manufactured and delivered at scale. Orca-T is an investigational alternative to traditional bone marrow transplants for blood cancers such as AML, ALL, and MDS. It uses a carefully selected mix of donor immune cells to lower the risk of graft-versus-host disease (GVHD). In an

Treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are moving from traditional chemoimmunotherapy (CIT) to targeted drugs. The BRUIN CLL-313 Phase III study tested pirtobrutinib, a new noncovalent Bruton tyrosine kinase inhibitor (ncBTKi), in patients who had never received treatment before. The study compared pirtobrutinib alone to bendamustine plus rituximab (BendaR), a

The 5-year results of the CheckMate 274 trial show that adjuvant nivolumab (Opdivo) provides lasting benefits for patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery. With nearly five years of follow-up, nivolumab significantly improved outcomes compared with placebo. The median disease-free survival was 21.9 months with nivolumab, compared with 11.0 months with placebo—almost double.

New data from a phase 1/2 study presented at the Transplantation & Cellular Therapy Meetings show that the bispecific CAR T-cell therapy LV20.19 is highly effective for patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), but it also brings important safety concerns. In the study of 18 patients who had received a median of

In 2026, first-line treatment for metastatic pancreatic cancer has expanded from two main options to three. Doctors must choose carefully because there is still no perfect biomarker to guide decisions. The approval of NALIRIFOX in February 2024, based on the NAPOLI 3 trial, added a new standard to existing treatments. The three main frontline regimens

A Phase 2 trial shows that a fixed-duration combination of obinutuzumab and venetoclax is highly effective for untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL). All patients responded to treatment, with 90% achieving complete or near-complete remission and 100% reaching undetectable levels of residual disease by the ninth cycle. Three months after treatment,

A recent study suggests that Brukinsa (zanubrutinib) provides better progression-free survival than other BTK inhibitors in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The study compared zanubrutinib with Calquence (acalabrutinib) and Imbruvica (ibrutinib) by adjusting data from three major Phase 3 trials—ALPINE, ELEVATE-RR, and ASCEND—to make fair comparisons. The results showed that zanubrutinib reduced